H.C. Wainwright Maintains Buy Rating on Tempus AI (TEM) Following Strong Revenue Growth

Tempus AI, Inc. (NASDAQ:TEM) ranks among the best short squeeze stocks to invest in. Following the company’s first-quarter results, H.C. Wainwright reduced its price target for Tempus AI, Inc. (NASDAQ:TEM) to $64 from $95 while retaining a Buy rating on the company’s shares. Tempus AI, Inc. (NASDAQ:TEM) posted total revenue of $348.1 million in Q1, up 36.1% year-over-year and above H.C. Wainwright’s expectation of $345.3 million.

On the other hand, the company reported a net loss of $125.9 million, or $0.71 per diluted share, which was greater than H.C. Wainwright’s expected loss of $84.7 million. The firm stated that the operating loss has increased in comparison to previous quarters.

Tempus AI, Inc. (NASDAQ:TEM) expanded a number of partnerships during the quarter, including its collaboration with Gilead to offer enterprise-wide accessibility to its AI-driven Lens platform and a multi-year strategic partnership with Merck to expedite biomarker discovery and development. In addition, the company revealed results from the ALERT trial with Medtronic, which showed that its AI-driven EHR alerts improved life-saving heart valve operations by 40%.

Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company that uses artificial intelligence to advance precision medicine.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.